MX2022016427A - Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. - Google Patents

Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.

Info

Publication number
MX2022016427A
MX2022016427A MX2022016427A MX2022016427A MX2022016427A MX 2022016427 A MX2022016427 A MX 2022016427A MX 2022016427 A MX2022016427 A MX 2022016427A MX 2022016427 A MX2022016427 A MX 2022016427A MX 2022016427 A MX2022016427 A MX 2022016427A
Authority
MX
Mexico
Prior art keywords
compounds
glycolate oxidase
disease
treatment
oxidase inhibitors
Prior art date
Application number
MX2022016427A
Other languages
English (en)
Inventor
Bing Wang
Qi Chao
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2022016427A publication Critical patent/MX2022016427A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En este documento se describen compuestos, métodos para fabricar dichos compuestos, composiciones farmacéuticas y medicamentos que contienen dichos compuestos, y métodos para usar dichos compuestos para tratar o prevenir enfermedades o trastornos asociados con la enzima glicolato oxidasa (GO). Dichas enfermedades o trastornos incluyen, por ejemplo, trastornos del metabolismo del glioxilato, incluida la hiperoxaluria primaria, que están asociados con la producción de cantidades excesivas de oxalato.
MX2022016427A 2017-12-29 2020-07-13 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. MX2022016427A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762611995P 2017-12-29 2017-12-29
US201862765313P 2018-08-20 2018-08-20

Publications (1)

Publication Number Publication Date
MX2022016427A true MX2022016427A (es) 2023-01-30

Family

ID=65234672

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2020006414A MX2020006414A (es) 2017-12-29 2018-12-28 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2022016427A MX2022016427A (es) 2017-12-29 2020-07-13 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2022016463A MX2022016463A (es) 2017-12-29 2020-07-13 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2022016422A MX2022016422A (es) 2017-12-29 2020-07-13 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2022016434A MX2022016434A (es) 2017-12-29 2020-07-13 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2022016415A MX2022016415A (es) 2017-12-29 2020-07-13 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020006414A MX2020006414A (es) 2017-12-29 2018-12-28 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.

Family Applications After (4)

Application Number Title Priority Date Filing Date
MX2022016463A MX2022016463A (es) 2017-12-29 2020-07-13 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2022016422A MX2022016422A (es) 2017-12-29 2020-07-13 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2022016434A MX2022016434A (es) 2017-12-29 2020-07-13 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2022016415A MX2022016415A (es) 2017-12-29 2020-07-13 Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.

Country Status (17)

Country Link
US (3) US11384055B2 (es)
EP (1) EP3732167A2 (es)
JP (2) JP7344878B2 (es)
KR (1) KR20200112860A (es)
CN (6) CN117024420A (es)
AR (1) AR114070A1 (es)
AU (1) AU2018395275A1 (es)
BR (1) BR112020013073A2 (es)
CA (1) CA3086401A1 (es)
CL (1) CL2020001742A1 (es)
IL (3) IL297802A (es)
MA (1) MA51418A (es)
MX (6) MX2020006414A (es)
PE (1) PE20201500A1 (es)
SG (1) SG11202005807QA (es)
TW (2) TW202340155A (es)
WO (1) WO2019133770A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006414A (es) * 2017-12-29 2020-09-17 Biomarin Pharm Inc Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
US11389456B2 (en) 2018-02-23 2022-07-19 Oxalurx, Inc. Compounds and methods for treating oxalate-related diseases
EP3817816A1 (en) * 2018-07-06 2021-05-12 Orfan Biotech Inc. Triazole glycolate oxidase inhibitors
US11504367B2 (en) * 2019-08-22 2022-11-22 Oxalurx, Inc. Compounds and methods for treating oxalate-related diseases
JP7439248B2 (ja) * 2019-11-01 2024-02-27 ライラック セラピューティクス， インク． グリコール酸オキシダーゼ阻害剤としてのヘテロ環式カルボキシレート化合物
AU2021205916A1 (en) * 2020-01-08 2022-08-25 Cantero Therapeutics, Inc. Processes for preparing triazole glycolate oxidase inhibitors
CN115702146B (zh) * 2020-06-30 2024-10-18 苏州恩华生物医药科技有限公司 5-((1,2,3,4-四氢异喹啉-7-基)氨基)吡啶-2(1h)-酮衍生物及其应用
WO2022066933A1 (en) * 2020-09-24 2022-03-31 Chinook Therapeutics Canada, Inc. Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof
CN114478210A (zh) * 2022-02-26 2022-05-13 江苏壹药新材料有限公司 一种7-氯萘-2-甲醛的合成方法
WO2023170024A1 (en) * 2022-03-11 2023-09-14 University Of Copenhagen Camk2 modulators and their use in medicine
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs
WO2024109917A1 (zh) * 2022-11-25 2024-05-30 西藏海思科制药有限公司 一种三唑衍生物及其在医药上的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US149223A (en) * 1874-03-31 Improvement in axles for vehicles
DE2860722D1 (en) * 1977-11-10 1981-08-27 Beecham Group Plc Triazolo-quinoline derivatives, processes for their preparation and their pharmaceutical use
DE2757929A1 (de) * 1977-12-24 1979-07-05 Boehringer Sohn Ingelheim Neue pyrido-eckige klammer auf 1,2-a eckige klammer zu -v-triazolo- eckige klammer auf 4,5-d eckige klammer zu pyrimidinone, deren salze und verfahren zu deren herstellung
JPS5519292A (en) * 1978-07-24 1980-02-09 Beecham Group Ltd Benzopyranotriazoles*their manufacture and medical composition containing them
EP0007727B1 (en) * 1978-07-24 1983-11-30 Beecham Group Plc Benzopyranotriazoles, preparation of these compounds and pharmaceutical composition containing them
US4431660A (en) 1979-06-11 1984-02-14 Merck & Co., Inc. (4'-Biphenylyloxy and-thio-oxy)-3-hydroxy-3-pyrroline-2,5-diones and a method of treating calcium oxalate renal lithiasis therewith
US4349561A (en) 1979-11-05 1982-09-14 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
IL61897A (en) * 1980-01-19 1984-01-31 Beecham Group Ltd Benzopyrano(2,3-d)-v-triazoles,their production and pharmaceutical compositions containing them
EP0032821B1 (en) * 1980-01-19 1985-04-10 Beecham Group Plc Substituted benzopyranotriazoles
NZ199139A (en) * 1980-12-13 1985-01-31 Beecham Group Ltd Benz(phenoxyalkoxy)-9-oxo-1h,9h-benzopyrano-(2,3-d)-v-triazoles
US4431652A (en) 1980-12-29 1984-02-14 Merck & Co., Inc. 4-Hydroxy-5-substituted-3(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
US4428956A (en) 1980-12-29 1984-01-31 Merck & Co., Inc. 4-Hydroxy-5-substituted-3-(2H)-isothiazolone-1,1-dioxide derivatives useful in treating urinary tract calcium oxalate lithiasis
JPS57158788A (en) * 1981-03-03 1982-09-30 Beecham Group Ltd Novel compound, manufacture and medicinal composition containing same
WO1993017681A1 (en) * 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
CA2445568A1 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
JP4075357B2 (ja) * 2001-11-15 2008-04-16 宇部興産株式会社 ４，５−ジ置換−１，２，３−トリアゾール及びその製造法
MXPA05006354A (es) * 2002-12-13 2005-08-26 Smithkline Beecham Corp Antagonistas ccr5 como agentes terapeuticos.
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0603891D0 (en) * 2006-02-27 2006-04-05 Syngenta Ltd Novel herbicides
US8450350B2 (en) * 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
CA2869541A1 (en) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-alkyltriazole compounds as lpar antagonists
KR101537296B1 (ko) * 2012-10-26 2015-07-17 삼성전자 주식회사 반도체 나노결정 및 그 제조방법
TW201418242A (zh) * 2012-10-26 2014-05-16 Du Pont 作為除草劑之經取代的三唑
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
EP3386949A4 (en) * 2015-12-07 2019-11-20 Wake Forest University Health Sciences GLYCOLATE OXIDASE INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF RENAL CALCULATIONS
CN105541796B (zh) * 2016-03-03 2017-11-14 武汉工程大学 一种nh‑1,2,3‑三唑联吡啶化合物的合成方法
CN105669569B (zh) * 2016-03-03 2017-12-12 武汉工程大学 一种nh‑1,2,3‑三唑化合物的合成方法
MX2020006414A (es) * 2017-12-29 2020-09-17 Biomarin Pharm Inc Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2021015874A (es) * 2019-06-19 2022-02-03 Biomarin Pharm Inc Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.

Also Published As

Publication number Publication date
WO2019133770A2 (en) 2019-07-04
JP2023159181A (ja) 2023-10-31
KR20200112860A (ko) 2020-10-05
SG11202005807QA (en) 2020-07-29
CN117024420A (zh) 2023-11-10
RU2020120974A3 (es) 2022-01-31
MX2022016422A (es) 2023-01-30
CN117069712A (zh) 2023-11-17
MX2020006414A (es) 2020-09-17
TWI811282B (zh) 2023-08-11
MX2022016415A (es) 2023-01-30
US20210171474A1 (en) 2021-06-10
CN117126151A (zh) 2023-11-28
EP3732167A2 (en) 2020-11-04
AU2018395275A1 (en) 2020-07-16
MX2022016434A (es) 2023-01-30
IL275496A (en) 2020-08-31
PE20201500A1 (es) 2020-12-29
TW202340155A (zh) 2023-10-16
TW201930272A (zh) 2019-08-01
CN111788187A (zh) 2020-10-16
US11384055B2 (en) 2022-07-12
JP7344878B2 (ja) 2023-09-14
CN117069713A (zh) 2023-11-17
RU2020120974A (ru) 2022-01-31
CA3086401A1 (en) 2019-07-04
MA51418A (fr) 2020-11-04
WO2019133770A3 (en) 2019-08-15
MX2022016463A (es) 2023-02-01
CL2020001742A1 (es) 2021-01-29
IL297802A (en) 2022-12-01
US20230089374A1 (en) 2023-03-23
AR114070A1 (es) 2020-07-15
CN117126152A (zh) 2023-11-28
JP2021509401A (ja) 2021-03-25
IL297788A (en) 2022-12-01
US20230079913A1 (en) 2023-03-16
BR112020013073A2 (pt) 2020-12-01

Similar Documents

Publication Publication Date Title
MX2022016427A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2021015874A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
EP4219713A3 (en) Products and compositions
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2021009555A (es) Ligandos de pseudocinasa tyk2.
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
MX2021013602A (es) Inhibidores de jak.
MX2022000712A (es) Moduladores de nlrp3.
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2021008941A (es) Moduladores gpr35.
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.